Peter S. McPherson

McGill University
Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Genetic studies have identified hundreds of risk genes for neurodegenerative diseases, yet translating these variants into disease mechanisms remains limited by incomplete knowledge of the protein products. Here, we present the ALS-Reproducible Antibody Platform (ALS-RAP), a systematic effort to characterize 303 antibodies targeting 33 amyotrophic lateral sclerosis (ALS) risk genes: ACSL5, ALS2, ANG, ANXA11, ATXN2, C9orf72, CAV1, CCNF, CHCHD10, CHMP2B, FIG4, FUS, HNRNPA1, HNRNPA2B1, KIF5A, LGALS1, MATR3, NEK1, OPTN, PFN1, SETX, SIGMAR1, SOD1, SPG11, SQSTM1, TAF15, TARDBP, TBK1, TIA1, TUBA4A, UBQLN2, VAPB, and VCP using knockout-based characterization to identify high-quality reagents in common applications. Using these antibodies, we profiled protein expression across human iPSC-derived and primary neurological cell types. Protein-level analyses revealed diverse cell type-specific expression patterns, with subsets of ALS-associated proteins enriched in glial or neuronal populations. This work provides a validated antibody toolbox and ALS protein resource for translating genetic risk into mechanistic insights.

Year:

2025

Antibody-based research applications are critical for biological discovery. Yet, there are no industry standards to compare the performance of antibodies in various applications. We describe a knockout cell line-based antibody characterization platform, developed, and approved jointly by industry and academic researchers that enables the systematic comparison of antibody performance in western blot, immunoprecipitation, and immunofluorescence procedures. The scalable protocols consist of (i) the identification of appropriate cell lines for antibody characterization studies, (ii) development/contribution of isogenic knockout controls, validated at the protein level, and (iii) a series of antibody characterization procedures focused on the most common uses of antibodies in research. Guidelines for the assessment of antibody performance are presented along with the value of making the resulting data publicly available. This antibody characterization platform can be implemented with minimal technological limitations. The proposed antibody characterization platform may be performed readily on antibodies targeting a protein in roughly one month, with one person working less than full-time. Antibody characterization is needed to meet standards for resource validation and data reproducibility, increasingly required by journals and funding agencies.

Year:

2024

Lysosomes help maintain cellular proteostasis, and defects in lysosomal positioning and function can cause disease, including neurodegenerative disorders. The spatiotemporal distribution of lysosomes is regulated by small GTPases including Rabs, which are activated by guanine nucleotide exchange factors (GEFs). DENN domain proteins are the largest family of Rab GEFs. Using a cell-based assay, we screened DENND6A, a member of the DENN domain protein family against all known Rabs and identified it as a potential GEF for 20 Rabs, including Rab34. Here, we demonstrate that DENND6A activates Rab34, which recruits a RILP/dynein complex to lysosomes, promoting lysosome retrograde transport. Further, we identify DENND6A as an effector of Arl8b, a major regulatory GTPase on lysosomes. We demonstrate that Arl8b recruits DENND6A to peripheral lysosomes to activate Rab34 and initiate retrograde transport, regulating nutrient-dependent lysosomal juxtanuclear repositioning. Loss of DENND6A impairs autophagic flux. Our findings support a model whereby Arl8b/DENND6A/Rab34-dependent lysosomal retrograde trafficking controls autophagy.

Year:

2024

Primary cilia are sensory antennae crucial for cell and organism development, and defects in their biogenesis cause ciliopathies. Ciliogenesis involves membrane trafficking mediated by small guanosine triphosphatases (GTPases) including Rabs, molecular switches activated by guanine nucleotide exchange factors (GEFs). The largest family of Rab GEFs is the DENN domain–bearing proteins. Here, we screen all 60 Rabs against two major DENN domain families using a cellular GEF assay, uncovering 19 novel DENN/Rab pairs. The screen reveals Rab10 as a substrate for DENND2B, a protein previously implicated in cancer and severe mental retardation. Through activation of Rab10, DENND2B represses the formation of primary cilia. Through a second pathway, DENND2B functions as a GEF for RhoA to control the length of primary cilia. This work thus identifies an unexpected diversity in DENN domain–mediated activation of Rabs, a previously unidentified non-Rab substrate for a DENN domain, and a new regulatory protein in primary ciliogenesis.

Year:

2022

Collaborators (12)

Carolyn Marks

Karolinska Institutet

SWEDEN
View details

Thomas M. Durcan

Associate Professor

Montreal Neurological Institute and Hospital

CANADA
View details

Luke Michael Healy

-

CANADA
View details

Anita Bandrowski

University of California, San Diego

UNITED STATES
View details

Carl Laflamme

Assistant Professor

University of Ottawa

CANADA
View details

Opher Gileadi

Head, Protein Sciences

Karolinska Institutet

SWEDEN
View details

Edward A. Fon

Professor

Montreal Neurological Institute and Hospital

CANADA
View details

Claire M Brown

Professor

McGill University

CANADA
View details

Guy A Rouleau

Professor

McGill University

CANADA
View details

Brian D. Marsden

Associate Professor, Research Informatics

University of Oxford

UNITED KINGDOM
View details

Harvinder Virk

NIHR Academic Clinical Lecturer (Respiratory Medicine)

University of Leicester

UNITED KINGDOM
View details

Susanne Graslund

Karolinska Institutet

SWEDEN
View details